- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Shifts Away From R-CHOP Treatment Shows Improved EFS and OS Benefit in MCL
September 24, 2021
Results from a mantle cell lymphoma study provide critical real-world evidence for improved outcomes with evolving patterns of care in patients with mantle cell lymphoma, according to the study authors.
ACCC Releases Five Abstracts at ASCO Quality Care Symposium
September 24, 2021
ACCC announces the release of five abstracts to be presented during the ongoing ASCO Quality Care Symposium.
Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment?
September 24, 2021
Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape.
Frontline Olaparib Plus Abiraterone Significantly Improves rPFS in mCRPC
September 24, 2021
The phase 3 PROpel clinical trial has achieved its primary end point of improvement in radiographic progression-free survival in men with metastatic castration resistant prostate cancer using the novel combination of olaparib and abiraterone.
FDA Approves First AI Device to Assist With Prostate Cancer Detection
September 24, 2021
The FDA authorized the marketing of Paige Prostate, the first ratification-intelligence-based software designed to identify areas with high likelihood of cancer on images from a prostate biopsy.
Adding Parsaclisib to Ruxolitinib May Reduce Spleen Size in Myelofibrosis
September 24, 2021
Add-on parsaclisib showed improvement in spleen volume and symptoms in patients with myelofibrosis who were having a suboptimal response to a stable dose of ruxolitinib.
Prostate Cancer Awareness Month: Advances Seen in Screening, Later-line Treatments
September 24, 2021
In an interview with Targeted Oncology, Ashley E. Ross, MD, PhD, discusses new prostate cancer screening and staging options as well as therapies for both earlier and later-stage disease.
Future of AML Management
September 24, 2021
Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.
Considerations in Choosing Venetoclax for AML
September 24, 2021
An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.
VIALE-A Trial: Acute Myeloid Leukemia
September 24, 2021
Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.
Frontline Treatment Options in AML
September 24, 2021
A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.
Biomarker Testing in AML
September 24, 2021
Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.